June 16, 2020
Mitsubishi Tanabe Pharma said on June 15 that its US subsidiary has begun a multinational PIII study of its investigational compound MT-7117 (dersimelagon) for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The company aims to file the...read more